Inflammatory Disease Rx Gets Green Light
The US Food and Drug Administration (FDA) has approved a new medication to treat multiple chronic inflammatory diseases.
Another Biosimilar Gets a Green Light
The US Food and Drug Administration (FDA) has approved another biosimilar. This one is meant to treat multiple conditions that affect the immune system.
Green Light for Biosimilar to Humira
The US Food and Drug Administration has approved its fourth biosimilar.
Second Biosimilar Gets FDA Nod
The US Food and Drug Administration (FDA) has approved the second-ever biosimilar, and it's meant to treat multiple conditions that affect the immune system.
How Dermatologists Could Help IBD Patients
Skin lesions are a common but unpleasant side effect of the anti-TNF drugs often used to treat patients with inflammatory bowel disease (IBD). But discontinuing treatment is not recommended.
Strong Acne Meds Okay for Gastro Tract
When birth control pills can't clear up acne in women, a stronger medicine is the next step. But doctors and patients have been concerned about a few of these medicines and their possible links to inflammatory bowel diseases (IBD).
No Safety Surprises from Humira
Humira (adalimumab) is a medication used to treat a variety of diseases. As the medication is being prescribed to more and more patients, researchers wanted to see if there were any side effects they didn't know about before.
New Drug for Crohn's Patients
Maybe this is the end of long-term stomach aches and pains, at least for patients with Crohn's disease who don't respond to the common treatment.
Affected On the Out and In
What happens on the outside can affect us on the inside. And it happens both ways, specifically among patients with psoriasis and inflammatory bowel diseases.
FDA Focus on TNF Blockers
A class of drugs is now under suspicion of causing cancer in children, adolescents and young adults under the age of 30. These are called Tumor Necrosis Factor (TNF) blockers, and the U.S. Food and Drug Administration (FDA) recently released an update regarding its ongoing safety review of these drugs.